文献速递心力衰竭与心肌病

转甲状腺素蛋白淀粉样变心肌病的自然史、生活质量与结局

Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.
PubMed 文献 · Circulation · 2019-05-21

该研究纳入英国国家淀粉样变中心2000至2017年的711例野生型、205例V122I遗传型和118例非V122I遗传型ATTR-CM患者,进行前瞻性方案评估。结果显示诊断延迟显著,诊断前3年内患者使用医院服务中位数17次,42%的野生型患者在出现心脏症状后>4年才确诊;V122I型患者功能受损更重、生活质量下降更明显且生存更差。ATTR-CM呈进行性且最终致命,需提高认识和广泛使用经验证的影像诊断方法。

要点

  • ATTR-CM诊断常延迟多年,诊断前3年内患者使用医院服务中位数达17次。
  • 42%的野生型ATTR-CM患者在出现心脏症状后>4年才确诊。
  • V122I遗传型患者诊断时功能与心脏指标更差,生活质量下降更明显,生存更差。

核心结论

  • ATTR-CM是一种进行性且最终致命的心肌病,与生活质量差相关,诊断常在症状出现后延迟多年。

研究设计与样本

  • 研究纳入英国国家淀粉样变中心2000至2017年的711例野生型ATTR-CM、205例V122I遗传型ATTR-CM和118例非V122I遗传型ATTR-CM患者,进行前瞻性方案评估,包括心脏参数、6分钟步行试验、堪萨斯城心肌病问卷生活质量和生存。

主要发现

  • 诊断延迟显著,诊断前3年内患者使用医院服务中位数(四分位距)为17(9-27)次,此时生活质量差。
  • 42%的野生型ATTR-CM患者在出现心脏症状后>4年才确诊。
  • 与其它亚组相比,V122I遗传型患者诊断时功能受损更重(P<0.001)、心脏疾病指标更差(P<0.001)、生活质量下降更明显且生存更差(P<0.001)。

临床怎么用

  • 需提高对ATTR-CM的认识,并广泛使用近期经验证的影像诊断方法,以使患者从新治疗进展中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure in older individuals. We sought to characterize the natural history of ATTR-CM and compare outcomes and quality of life among patients with acquired and hereditary forms of the disease. METHODS: We studied 711 patients with wild-type ATTR-CM, 205 with hereditary ATTR-CM associated with the V1221 variant (V122I-hATTR-CM), and 118 with non-V122I-hATTR-CM at the UK National Amyloidosis Center between 2000 and 2017. Patients underwent prospective protocolized evaluations comprising assessment of cardiac parameters, functional status by 6-minute walk test, quality of life according to the Kansas City Cardiomyopathy Questionnaire, and survival. Hospital service usage pre- and postdiagnosis was established using English central health records in a subset of patients. RESULTS: There was substantial diagnostic delay, with patients using hospital services a median (interquartile range) of 17 (9-27) times during the 3 years before diagnosis, by which time quality of life was poor; diagnosis of wild-type ATTR-CM was delayed >4 years after presentation with cardiac symptoms in 42% of cases. Patients with V122I-hATTR-CM were more impaired functionally ( P<0.001) and had worse measures of cardiac disease ( P<0.001) at the time of diagnosis, a greater decline in quality of life, and poorer survival ( P<0.001) in comparison with the other subgroups. CONCLUSIONS: ATTR-CM is an inexorably progressive and eventually fatal cardiomyopathy associated with poor quality of life. Diagnosis is often delayed for many years after symptoms develop. Improved awareness and wider use of recently validated diagnostic imaging methods are urgently required for patients to benefit from recent therapeutic developments.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Lane T, Fontana M, Martinez-Naharro A, et al. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation. 2019. PMID: 31109193. doi:10.1161/CIRCULATIONAHA.118.038169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。